Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Convalescent Plasma-Maranatha Christian University-COVID-19 refers to a specific convalescent plasma therapy evaluated by researchers at Maranatha Christian University in Indonesia. This biologic therapy utilizes plasma collected from individuals who have recovered from COVID-19, which contains high titers of polyclonal neutralizing antibodies (specifically 1:320 in the studied cohort) against the SARS-CoV-2 virus. The treatment is administered intravenously to provide passive immunization, aiming to neutralize the virus and prevent the progression of severe disease in hospitalized, non-intubated patients. It has been utilized under emergency approval in Indonesia as part of a broader multicenter clinical evaluation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Convalescent Plasma-Maranatha Christian University-COVID-19.